Background Treatment delays in lung cancer care in the United States may be attributable to
a diverse range of patient, provider, and institutional factors, the precise contributions of …

Background Next generation sequencing (NGS) of tumor of patients with advanced non–
small cell lung cancer (NSCLC) is now a standard of care that informs the clinician on the …

Circulating tumor DNA (ctDNA)-based molecular profiling is rapidly gaining traction in
clinical practice of advanced cancer patients with multi-gene next-generation sequencing …

Importance Molecular testing in non–small cell lung cancer (NSCLC) is commonly limited by
inadequate tumor sample. Plasma cell-free DNA (cfDNA) genotyping as a complementary …

AWPPH is a newly discovered long non‑coding (lnc) RNA that serves an oncogenic role in
the development of several types of cancer; however, its involvement in non‑small cell lung …

There is growing evidence that plasma cell‐free DNA testing can aid in the diagnosis of
targetable alterations at diagnosis in patients with advanced nonsquamous lung carcinoma …

Introduction EGFR exon 20 insertions (EGFRex20ins) are a diverse set of mutations in
NSCLC that are refractory to tyrosine kinase inhibitors. We describe real-world …

BACKGROUND: Comprehensive genomic profiling (CGP) is a next-generation sequencing-
based methodology that detects 4 classes of genomic alterations, as well as gene signature …

This study determined the frequency and factors associated with EGFR testing rates and
erlotinib treatment as well as associated survival outcomes in patients with non small cell …

The purpose of this study was to investigate the role of miR-760 in non-small cell lung
cancer (NSCLC), as well as relevant molecular mechanisms. Expression patterns of miR …